


# 2023 MTM Pharmacy Partners in Excellence Executive Overview, Targets, and Methodology

## Overview

The Partners in Excellence program forms the basis for HealthPartners' financial and public recognition for pharmacy practices providing exceptional clinical quality and affordable care.

Our goal is to recognize and reward Medication Therapy Management (MTM) practices that deliver on the Triple Aim: To improve health while improving the affordability and consumer experience of health care.

Financial rewards are based on pharmacy practice performance as measured by HealthPartners using Minnesota Community Measurement and HealthPartners developed and reported measures.



## 2023 – Quality Dimension: *Health*

For the 2023 Partners in Excellence program, the focus is on recognizing performance within the quality dimension of health. Performance is assessed using a composite measure containing multiple individual quality measures. Performance is translated to a star rating for that composite measure overall.

This method balances a MTM practice's performance of providing quality care across multiple disease states and rewards for consistent top performance.

- The Health Quality Dimension consists of measures that have been grouped into a composite measure which includes individual quality measures applicable to MTM pharmacy practice.
- A *target rate* is set for the composite measure.
- Silver award level is earned when an overall four-star rating is achieved for the composite measure.
- Gold award level is available when an overall four-star rating is achieved for the composite measures and the group's Affordability Performance is greater than the target.

The following principles are used in the Partners in Excellence program:

- Use measures that are relevant and clear to pharmacy practices and consumers
- Use measures that are accurate, valid, reliable and obtainable
- Use established measures, those endorsed nationally or generally accepted national or regional standards
- Draw on a range of measures from a variety of sources, where possible, for a robust overall rating methodology
- Apply consistent measurement approaches and use scoring that avoids or minimizes subjectivity
- Disclose the methodology so it is transparent to pharmacy practices, consumers and employers
- Silver performance recognizes high quality care delivered in the Health dimension
- Gold performance recognizes high quality care delivered in the Health dimension and at an affordable cost.

## Quality Performance Evaluation Steps

### Quality Dimension: Health


*Individual measures are grouped into a single composite measure*

#### MTM Pharmacy Health Dimension Quality Composite Measure

✕ Rate of Optimal Care for Diabetes and Vascular Conditions

or

✕ Clinical Detail Submission Rate



### Quality Performance Assessment

*Performance on the applicable quality composite measure is assessed as either meeting or falling short of four-star performance.*

★★★★ Quality Performance  
Met

★★★★ Quality Performance  
Not Met



### Award Level Assessment

*MTM practices meeting the ★★★★★ quality performance are assessed using the affordability measure to determine award level and associated bonus pool payout amount.*

#### SILVER LEVEL PERFORMANCE

When a four-star quality rating is achieved and the MTM practice's performance does not meet the affordability target

★★★★ Quality Performance

AND

MTM Engagement Rate < target

#### GOLD LEVEL PERFORMANCE

When an overall four-star rating is achieved and the MTM practice's performance meets or exceeds the affordability target

★★★★ Quality Performance

AND

MTM Engagement Rate > = target

## Medication Therapy Management Pharmacy Measures and Targets

Full population measures are used in assessing quality cluster performance. Targets were determined by evaluating the actual rates of the full populations seen by each MTM pharmacy practice.

| <b>HEALTH</b>   |                     |    |     |        |
|---|---------------------|----|-----|--------|
| <i>Quality Composite Measure</i>  |                     |    |     |        |
| <i>MTM Practices with &gt; = 30 members with Diabetes or a Vascular Condition</i> |                     |    |     |        |
| Measure   | Performance Targets |    |     |        |
|   | ★                   | ★★ | ★★★ | ★★★★   |
| Rate of Optimal Care for Diabetes and Vascular Conditions <sup>1</sup>            | <47%                |    |     | >=47%  |
| <i>MTM Practices with &lt; 30 members with Diabetes or a Vascular Condition</i>   |                     |    |     |        |
| Measure   | Performance Targets |    |     |        |
|   | ★                   | ★★ | ★★★ | ★★★★   |
| Clinical Detail Submission Rate <sup>1</sup>                                      | < 90%               |    |     | >= 90% |

| <b>AFFORDABILITY</b>  |            |            |
|---|------------|------------|
| <i>Determining Award Level for MTM Practices with Four-Star Quality Performance</i> |            |            |
| Measure   | Target     |            |
|   | Gold       | Silver     |
| MTM Engagement Rate <sup>1</sup>  | Rate >=42% | Rate < 42% |

### Measure Source:

- 1 HealthPartners developed measure

## AWARD LEVEL CALCULATIONS

Bonus Pool payouts are based upon the MTM practice's performance on the applicable quality composite measure and the affordability measure. When a MTM practice achieves a four-star quality performance, they are eligible for a payout. The payout level (Silver or Gold) is determined by the pharmacy practice's affordability performance.

- Silver Level (four-star overall quality score and Gold level affordability target is not met) earns \$25 per engaged targeted member (maximum of \$40,000).
- Gold Level (four-star overall quality score and Gold level affordability target is met) earns \$50 per engaged targeted member (maximum of \$80,000).

# APPENDIX I: Detailed Methodology

## Program Eligibility

To be eligible for program inclusion in 2023, MTM Pharmacy Practices must provide care and have submitted CCD information accepted for at least 30 HealthPartners members.

## Measure Eligibility

- MTM Pharmacy Practices which provide care to fewer than 30 members with diabetes or a vascular condition will be subject to the Quality Measure “Clinical Detail Submission Rate”.
- MTM Pharmacy Practices which provide care to 30 or more members with diabetes or a vascular condition will be subject to the Quality Measure “Rate of Optimal Care for Diabetes and Vascular Conditions”.

## Measure Definitions

**Clinical Detail Submission Rate:** The percentage of members with diabetes or a vascular condition whose clinical details for optimal diabetes care and vascular care are submitted to HealthPartners via accepted Type 1, 4, and 5 CCD records during the measurement year. A member’s clinical details include:

- Blood pressure reading
- Tobacco use status
- Hemoglobin A1c (applies only to members with diabetes)

NOTE: Members who were enrolled in hospice at any point in the measurement year will be removed from the rate calculation. Members with less than 120 days of HealthPartners membership eligibility following the first MTM visit of the year will also be removed from the rate calculation unless all applicable clinical details have been submitted to HealthPartners via accepted Type 1, 4, and 5 CCD records within that 120 days timeframe.

**Rate of Optimal Care for Diabetes and Vascular Conditions:** The percentage of members age 18-75 years with diabetes or a vascular condition whose condition is optimally controlled as of the last day of the measurement period based upon accepted Type 1, 4, and 5 CCD records during the measurement year. Clinical details and optimal control is detailed below.

| Clinical Detail        | Optimal Control*                             |
|------------------------|--|
| Blood pressure reading | < 140 / 90                                   |
| Tobacco use status     | Tobacco free                                 |
| Hemoglobin A1c         | < 8% (applies only to members with diabetes) |

\*most recent result of the calendar year on or after the date an MTM visit has occurred

NOTE: Members who were enrolled in hospice at any point in the measurement year will be removed from the rate calculation. Members with less than 120 days of HealthPartners membership eligibility following the first MTM visit of the year will also be removed from the rate calculation unless (1) all applicable clinical details have been submitted to HealthPartners via accepted Type 1, 4, and 5 CCD records within that 120 days timeframe and (2) those Type 1, 4, and 5 CCD records indicate optimal control.

**MTM Engagement Rate:** The percentage of assigned targeted members engaged in medication therapy management services during the measurement year, as evidenced by Type 2 and Type 3 CCD records accepted by HealthPartners during the measurement year.

NOTE: Members who were enrolled in hospice at any point in the measurement year will be removed from the rate calculation unless there is a Type 2 and Type 3 CCD record accepted by HealthPartners for that member in the calendar year. Members with less than 60 days of HealthPartners membership eligibility in the measurement year will also be removed from the rate calculation unless there is a Type 2 and Type 3 CCD record accepted by HealthPartners in the measurement year.

**Definition of Diabetes or a Vascular Condition:** HealthPartners uses the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS) criteria to identify which members have a diabetes or a vascular condition for inclusion in the health quality measures. Additional HealthPartners developed criteria are used to remove members from the measure: specifically when a member is identified by HEDIS criteria based upon drug fills only and the only drug filled is an SGLT-2 inhibitor or GLP-1 agonist.

## APPENDIX II: Frequently Asked Questions

### *What data will be communicated with me?*

- Lists of assigned targeted members and their associated MTM visit statuses will be provided periodically throughout the calendar year.
- Final results will be available following the end of year in review.
- Lists of members you've seen who have diabetes or a vascular condition and their current status of meeting or not meeting the definition of optimal control based upon CCD records we've received.

### *Whom do I call if I have more questions?*

Please contact Nancy Jorgenson, Pharmacy Network Liaison, at 952-883-6838 or [Nancy.J.Jorgenson@HealthPartners.com](mailto:Nancy.J.Jorgenson@HealthPartners.com) with any questions.